WASHINGTON — The Association for Accessible Medicines and its members look forward to working with President-elect Biden’s U.S. Trade Representative (USTR)-designee Katherine Tai to ensure that U.S. trade policy promotes the proper balance between pharmaceutical innovation and off-patent competition that expands patient access to medicines and reduces health care costs.

USTR-designee Tai was an instrumental leader in ensuring that the U.S.-Mexico-Canada Agreement reflected this balance, and her nomination is a clear signal of the importance of this policy perspective in the Biden-Harris Administration.